Loading clinical trials...
Loading clinical trials...
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older
Conditions
Interventions
Investigational H7N1 vaccine GSK2789869A
Placebo
Locations
8
United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Meridian, Idaho, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Truro, Nova Scotia, Canada
Start Date
September 25, 2013
Primary Completion Date
December 4, 2013
Completion Date
October 23, 2014
Last Updated
November 17, 2017
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions